宫颈上皮内瘤变的研究概况及中西医结合治疗探讨

摘要/Abstract

摘要： 宫颈癌是常见的妇科恶性肿瘤，其发病年龄呈年轻化趋势，发病率在我国女性生殖系统恶性肿瘤中已升至第二位。宫颈上皮内瘤变（cervical intraepithelial neoplasia，CIN）与宫颈癌的发生密切相关，被视为癌前病变。对CIN的尽早发现、及时干预治疗，有助于及早、有效预防宫颈癌。本研究通过综述中西医对CIN的认识，CIN的干预和治疗方式，以及中西医结合治疗CIN的优势，以期为继续发挥中西医结合治疗的优势，推进中西医结合治疗CIN的发展，及早、有效预防宫颈癌提供参考与借鉴。

关键词: font-size:medium, ">宫颈上皮内瘤变；宫颈癌；中医治疗；西医干预；中西医结合治疗

Abstract: Cervical cancer is one of the most common gynecological malignancies. Its age of onset tends to be younger, and its incidence rate has raised to the second place among the female reproductive system malignancies in China. Cervical intraepithelial neoplasia(CIN) is closely associated with the development of cervical cancer and is considered as a precancerous lesion. Early detection of CIN and intervene treatment in time is helpful to prevent cervical cancer as early as possible and effectively. This study reviewed the knowledge of traditional Chinese medicine(TCM) and western medicine on CIN, the intervention and treatment of CIN, and the advantages of TCM and western medicine integrated treatment on CIN, in order to provide reference for giving full play to the advantages of TCM and western medicine in treating CIN, promoting the development of TCM and western medicine integrated treatment on CIN, and the early and effective prevention of cervical cancer.

Key words: Cervical intraepithelial neoplasia, Cervical carcinoma；Traditional Chinese medicine treatment, Western medicine intervention；Integrated traditional Chinese and western medicine

中图分类号:

张冠红, 高丽萍, 黄健妹. 宫颈上皮内瘤变的研究概况及中西医结合治疗探讨[J]. 中国医药导刊, 2021, 23(12): 902-906.

ZHANG Guanhong, GAO Liping, HUANG Jianmei. Overview of Researches on Cervical Intraepithelial Neoplasia and Discussion on Its Integrated Treatment of Traditional Chinese and Western Medicine[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2021, 23(12): 902-906.

参考文献

[1]谢幸,苟文丽.妇产科学[M].第8版.北京：人民卫生出版社，2013：301.
     [2]李莉娟,罗幼珍.宫颈癌的病因及防治的研究进展[J].现代医学与健康研究电子杂志,2019,3(24):16-19.
     [3]王鑫丹.宫颈癌病因诊断及防治的研究进展[J].基层医学论坛,2017,21(35):5008-5010.
     [4]谭寒星,黄利鸣,王艳林.子宫颈癌病因学研究进展[J].广东医学,2010,31(17):2309-2312.
     [5]Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer Journal for Clinicians, 2018,68(6):394-424
     [6]屈小会,刘东平,赵虹,等.宫颈上皮内瘤变患者中医证候分布规律探析[J].陕西中医药大学学报,2018,41(6);68-72.
     [7]朱丽红,邵文彬.从“虚则生疣”谈宫颈上皮内瘤变的病因病机[J].山东中医杂志,2013,32(12);863-864.
     [8]Zhang X，Xu Y，Meng T，et al. Analysis of factors affecting the prognosis of patients with cervical intraepithelial neoplasia 2[J].Oncol Lett，2020，20（2）：1810-1816.
     [9]郎景和.子宫颈上皮内瘤变的诊断与治疗[J].中华妇产科杂志,2001,36(5):261-263.
     [10]张琦.人乳头瘤病毒、液基薄层细胞学检测联合阴道镜在早期宫颈癌及宫颈上皮内瘤变筛查中的意义[J].中国妇幼保健 ,2018,33(6):1275-1277.
     [11]戴西湖,谢福安.妇科辨病专方治疗[M].第1版.人民卫生出版社,2000: 176-177.
     [12]刘婕,徐力.徐力运用“截断疗法”治疗宫颈人乳头瘤病毒感染经验撷菁[J].陕西中医,2021,42(1):106-108.
     [13]赵岷慧.扶正解毒汤治疗宫颈柱状上皮异位伴HR-HPV感染临床观察及对免疫细胞水平的影响[J].湖北中医药大学学报,2020,22(3):37-39.
     [14]林兰,汪敏华,黄烨,等.中药易黄汤治疗宫颈高危型人乳头瘤病毒感染的疗效观察[J].海峡药学,2021,33(3):117-119.
     [15]刘倩,吴冬梅,郑怡真(指导).郑怡真从湿热治疗高级别宫颈鳞状上皮内病变临证思路[J].福建中医药,2021,52(6):46-47.
     [16]冉雪梦,王伟,王世欣,等.清热解毒方治疗宫颈高危型人乳头瘤病毒感染的临床研究[J].中国中西医结合杂志,2018,38(4):421-424.
     [17]王瑞霞,温晋英,张淑芬.核异消颗粒治疗宫颈高危型HPV感染60例临床观察[J].中国中医药科技,2018,25(6):875-876.
     [18]范美霞,范朝霞.祛疣汤联合太诺清妇科白带片对妇科带下病合并宫颈高危型HPV感染患者的疗效观察[J].中医临床研究,2019,11(16):91-93.
     [19]武雪莲.加味易黄汤联合自制清毒方对宫颈HPV病毒感染患者病毒载量及TNF-α、hs-CRP水平的影响[J].光明中医,2021,36(1):84-86.
     [20]魏玮,刘晓莹.敷灸栓对宫颈上皮内瘤变及HPV感染人群的临床疗效[J].新疆中医药,2016,34(2):15-17.
     [21]贾平.干扰素阴道泡腾片治疗宫颈HPV感染观察［J］.中国卫生标准管理,2019,10(2):85-87.
     [22]徐静,魏敏敏.宫颈锥切术后通督扶正疗法联合干扰素对宫颈上皮内瘤变患者的疗效及生活质量的影响观察[J].中国社区医师,2021,37(5):101-102.
     [23]李书艳,李龙珠,顾海娜,等.重组人干扰素治疗宫颈上皮内瘤变Ⅰ的临床效果评价[J].中华医院感染学杂志,2021,31(5):749-752.
     [24]Jin N, Lera RF, Yan RE, et al. Chromosomal instability upregulates interferon in acute myeloid leukemia[J]. Genes, Chromosomes and Cancer, 2020,59(11):627-638.
     [25]张延霞,李剑锋,陈贤凤.分析重组人干扰素α-2b联合聚甲酚磺醛治疗宫颈上皮内瘤变Ⅰ～Ⅱ级的疗效[J].医学理论与实践,2020,33(19):3238-3240.
     [26]Schellenbacher C, Kwak K, Fink D, et al. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses［J］.J Invest Dermatol, 2013, 133(12):2706-2713.
     [27]Petrosky E, Bocchini JA, Hariri S, et al. Use of 9-valent human papillomavirus(HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices［J］. MMWR Morb Mortal Wkly Rep, 2015, 64(11):300-304.
     [28]王祎晨,诸一鸣,方晨燕,等.全子宫切除术治疗宫颈锥切术后诊断为宫颈上皮内瘤变或早期宫颈癌107例[J].浙江医学,2020,42(12):1318-1320.
     [29]韩松筠,孔为民,商文金.绝经后妇女宫颈上皮内瘤变Ⅲ级行全子宫切除术临床病理分析[J].中国临床医生杂志,2020,48(6):737-740.
     [30]Tommy RB,Abigail SZ,Leslie SM, et al. Risk of cervical and vaginal dysplasia after surgery for vulvar intraepithelial neoplasia or cancer: a 6 year follow-up study[J].Gynecol Oncol,2019,155(1):88-92.
     [31]樊丽萍,张忠明.LEEP术和子宫全切术治疗宫颈高级别上皮内瘤变的效果比较[J].临床医学研究与实践,2017,2(8):75-76.
     [32]Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women［J］.N Engl J Med, 2015, 372(8):711-723.
     [33]Bonanni P, Zanella B, Santomauro F, et al. Safety and perception: what are the greatest enemies of HPV vaccination programmes［J］.Vaccine, 2018, 36(36):5424-5429.
     [34]Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus(HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types(PATRICIA): final analysis of a double-blind, randomised study in young women［J］.Lancet, 2009, 374(9686):301-314.
     [35]张一萍,星丽娜,张云鹤.治疗性人类乳头瘤病毒疫苗研究进展[J].武警医学,2021,32(10):901-906.
     [36]Poelgeest MI,Welters MJ,Vermeij R,et al. Vaccination against oncoproteins of HPV16 for noninvasive vulvar/vaginal lesions: lesion clearance is related to the strength of the T-cell response[J]. Clin Cancer Res,2016,22(10):2342-2350.
     [37]Massarelli E,William W,Johnson F, et al. Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical trial[J].JAMA Oncol,2019,5(1):67-73.
     [38]Melief CJ,Welters MJ,Vergote I, et al. Strong vaccine responses during chemotherapy are associated with prolonged cancer survival [J]. Sci Transl Med,2020,12(535):eaaz8235.
     [39]Davidson EJ,Faulkner RL,Sehr P,et al.Effect of TA-CIN(HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV(vaccinia virus encoding HPV 16/18E6E7)[J].Vaccine,2004,22(21-22):2722-2729.
     [40]杨璇,杜冰心,汪翠萍,等.固本清毒汤治疗宫颈高危型人乳头瘤病毒感染临床观察[J].安徽中医药大学学报,2021,40(4):32-35.
     [41]王斐,王烈宏.中西医结合治疗西宁地区宫颈高危型HPV感染30例疗效分析[J].中国现代药物应用,2020,14(24):234-235.
     [42]林晓华,姚锐,胡慧娟,等.消毒汤联合干扰素治疗宫颈高危型人乳头瘤病毒感染30例观察[J].浙江中医杂志,2021,56(3):190-191.
     [43]马铁玉.宫颈上皮内瘤变手术患者术前接受清热解毒法联合微波治疗对创面愈合的影响[J].实用妇科内分泌杂志(电子版),2019,6(19):101.
     [44]冯碧波,翟建军,蔡昱.LEEP术联合芪苓方剂治疗宫颈上皮内瘤变的疗效研究[J].中国生育健康杂志,2019,30(4):332-337.
     [45]张卫丹,程亚丽,张琼.外用溃疡散联合LEEP术治疗宫颈上皮内瘤变临床研究[J].新中医,2020,52(8):116-118.
     [46]郭瑞,张俊丽.三花解毒饮联合尤靖安治疗湿热下注型轻中度宫颈上皮内瘤变合并高危型人乳头瘤病毒持续感染临床研究[J].新中医,2021,53(15):113-117.

快速检索引用检索图表检索高级检索